1. Scrip
  2. >>Therapy Areas

$2bn AbbVie Deal Puts I-Mab On Global Immuno-Oncology Map

Safety Of CD47 Asset A Major Attraction?

 
• By Ian Haydock

In another clear signal that China's innovative drug R&D is coming of age, most global rights to I-Mab's promising early-stage CD47 antibody have been picked up by AbbVie in a deal valued at close to $2bn.

CD47
CD47, The Subject Of Major New I-Mab/AbbVie Alliance • Source: Shutterstock

In what it says is the largest ever global out-licensing agreement by a Chinese biotech, I-Mab Biopharma Co., Ltd has entered into a global partnership with AbbVie Inc. for a CD47 antibody worth close to $2bn in total, including $200m upfront.

Reflecting investor confidence in its pipeline, the Shanghai-based immuno-oncology venture – formed just four years ago - has also separately completed the biggest ever private investment in public equity financing by a US-listed bioventure

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on Scrip for daily insights

  • Start your 7-day free trial
  • Explore trusted news, analysis, and insights
  • Access comprehensive global coverage
  • Enjoy instant access – no credit card required
Start Free Trial

Already a subscriber?

More from Immuno-oncology

More from Anticancer